NGNE241220C12500
- 0.00
- 0.000.00%
Neurogene Newsroom
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating
Neurogene Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $46 to $60
Neurogene Analyst Ratings
Positive Interim Clinical Data and Strategic Developments Justify Buy Rating for Neurogene
Positive Buy Rating for Taysha Gene Therapies Amidst Competitive Advantages Over Neurogene
Neurogene Price Target Raised to $72.00/Share From $45.00 by Leerink Partners
Neurogene (NGNE) Receives a Buy From Stifel Nicolaus
Baird Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $72
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN) and Neurogene (NGNE)
Neurogene Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $55
Neurogene Analyst Ratings
William Blair Sticks to Its Buy Rating for Neurogene (NGNE)